T
Description
Israeli late clinical-stage pharmaceutical company founded in 2016. Developing breakthrough immunomodulatory therapies for autoimmune and inflammatory ocular diseases. Lead compound TRS (INN: Dazdotuftide) in eye drop and intravitreal formulations. FDA SPA agreement for Phase 3 in non-infectious uveitis. Based in Zichron Yaacov.